TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9476183

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg/lansoprazole 15 mg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg/placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg/ranitidine 150 mg
Number of subjects: 132

Group type: COMPARATOR
Intervention: ranitidine 300 mg/placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: lansoprazole (half dose formulation)
Number of subjects: 132
Study: 7964842

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 3680603

Group type: EXPERIMENTAL
Intervention: Sublingual administration of 1 mg alprazolam
Number of subjects: 13

Group type: COMPARATOR
Intervention: Oral administration of 1 mg alprazolam
Number of subjects: 13
Study: 29950827

Group type: EXPERIMENTAL
Intervention: LLN+/FR+
Number of subjects: 2607

Group type: EXPERIMENTAL
Intervention: LLN-/FR+
Number of subjects: 2607

Group type: EXPERIMENTAL
Intervention: LLN-/FR-
Number of subjects: 2607

Group type: COMPARATOR
Intervention: LLN+/FR+ vs LLN-/FR-
Number of subjects: 2607

Group type: COMPARATOR
Intervention: LLN-/FR+ vs LLN+/FR+
Number of subjects: 2607
Study: 26771737

Group type: EXPERIMENTAL
Intervention: Citalopram (30 mg/day, titrated over 3 weeks)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 24410954

Group type: EXPERIMENTAL
Intervention: n-3 FA supplement (2.3 g daily for 6 months)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 22818964

Group type: EXPERIMENTAL
Intervention: Mitroflow valve
Number of subjects: 276
Study: 20350147

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg once daily
Number of subjects: 596

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596
Study: 18595291

Group type: EXPERIMENTAL
Intervention: Choice of tasks from a list
Number of subjects: 3

Group type: COMPARATOR
Intervention: Yoked-control condition (tasks assigned by a trainer)
Number of subjects: 3
Study: 16086704

Group type: EXPERIMENTAL
Intervention: 7-day rabeprazole-based triple therapy (rabeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g, all twice a day)
Number of subjects: 458

Group type: COMPARATOR
Intervention: 10-day rabeprazole-based triple therapy (rabeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g, all twice a day)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: 7-day rabeprazole-based triple therapy
Number of subjects: 458

Group type: COMPARATOR
Intervention: 10-day rabeprazole-based triple therapy
Number of subjects: 458
Study: 11744802

Group type: EXPERIMENTAL
Intervention: Chronic intake of vegetable protein added to animal protein diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Substituting vegetable protein for some of the animal protein in the diet
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control dietary program (not specified in detail)
Number of subjects: 14
Study: 10075960

Group type: EXPERIMENTAL
Intervention: Functional Digestive Disorders Quality of Life Questionnaire (FDDQL)
Number of subjects: 401
Study: 8834642

Group type: COMPARATOR
Intervention: Hypertensive patients with glomerulonephritis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normotensive patients with glomerulonephritis
Number of subjects: 0
Study: 2184180

Group type: EXPERIMENTAL
Intervention: Anterior Q wave infarction
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Inferoposterior Q wave infarction
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Non-Q wave infarction
Number of subjects: 777
Study: 6116728

Group type: EXPERIMENTAL
Intervention: Hydroxyzine pamoate (25 mg q.i.d.) + cimetidine (300 mg q.i.d.)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Hydroxyzine pamoate (25 mg q.i.d.) + placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydroxyzine pamoate (25 mg q.i.d.) + terbutaline (2.5 mg q.i.d.)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydroxyzine pamoate (25 mg q.i.d.) + cyproheptadine (4 mg q.i.d.)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydroxyzine pamoate (25 mg q.i.d.) + chlorpheniramine (4 mg q.i.d.)
Number of subjects: 19
Study: 30280927

Group type: COMPARATOR
Intervention: Maternal prepregnancy overweight/obesity (BMI ≥ 25 kg/m2)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Normal weight women
Number of subjects: 194
Study: 28130627

Group type: COMPARATOR
Intervention: Traditional Resistance Training (TRAD)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Crescent Pyramid (CP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Drop-Set (DS)
Number of subjects: 32
Study: 24941138

Group type: EXPERIMENTAL
Intervention: Black cohosh extract 40 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 23328330

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 to 50 mg/d)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Divalproate (500 to 750 mg/d)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 448
Study: 21461792

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (2 μg·kg(‐1) and 4 μg·kg(‐1) combined)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (2 μg·kg(‐1))
Number of subjects: 101

Group type: COMPARATOR
Intervention: Fentanyl (1 μg·kg(‐1))
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 101
Study: 19125241

Group type: EXPERIMENTAL
Intervention: 150 mg idebenone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 750 mg idebenone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: idebenone (up to 2,250 mg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: idebenone
Number of subjects: 25
Study: 17910227

Group type: EXPERIMENTAL
Intervention: Dentin adhesives and a dentin desensitizer
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 55
Study: 14752632

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted technique for primary placement of the peritoneal portion of shunt catheter (n=11)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted technique for evaluation of shunt patency and repositioning (n=6)
Number of subjects: 17
Study: 11707794

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 10 microg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural bupivacaine 0.25%, 12 mL
Number of subjects: 30
Study: 9489599

Group type: EXPERIMENTAL
Intervention: 750 microg hydroxocobalamin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1500 microg hydroxocobalamin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 750 microg to 1500 microg hydroxocobalamin
Number of subjects: 10
Study: 7811785

Group type: EXPERIMENTAL
Intervention: Slowed respiration rate (RR) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional frontal electromyographic (EMG) biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no feedback)
Number of subjects: 0
Study: 3197368

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31329360

Group type: EXPERIMENTAL
Intervention: Nintedanib (continuation from INPULSIS®)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Nintedanib (initiation in INPULSIS®‐ON after placebo)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Nintedanib (continuation in INPULSIS®‐ON)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo (in INPULSIS®)
Number of subjects: 215
Study: 30544518

Group type: EXPERIMENTAL
Intervention: DHA supplementation (0 to 7 mg/kg/day for six months)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control (no DHA supplementation)
Number of subjects: 109
Study: 26746147

Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 100
Study: 24238592

Group type: EXPERIMENTAL
Intervention: Push as hard as you can
Number of subjects: 13

Group type: COMPARATOR
Intervention: Push down firmly 5 cm
Number of subjects: 13
Study: 24397061

Group type: EXPERIMENTAL
Intervention: Local steroid injection (triamcinolone 20 mg mixed with lignocaine 2% 1 cc) and topical NSAID cream (diclofenac diethylammonium) twice a day, tab. diclofenac sodium 50 mg twice a day for 3 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tab diclofenac 50 mg twice a day and topical NSAID cream application twice a day for 3 weeks
Number of subjects: 60
Study: 19935437

Group type: EXPERIMENTAL
Intervention: Integrated Medical Learning (IML) educational intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Premeeting knowledge assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert opinion presentations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postmeeting surveys
Number of subjects: 0
Study: 18706164

Group type: EXPERIMENTAL
Intervention: OROS‐MPH (18 mg/time, once daily)
Number of subjects: 99

Group type: COMPARATOR
Intervention: IR‐MPH (5 mg/time, twice or three times per day)
Number of subjects: 99
Study: 15482357

Group type: EXPERIMENTAL
Intervention: Effervescent ASA (1000 mg)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Sumatriptan (50 mg)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 11182878

Group type: EXPERIMENTAL
Intervention: PAS intervention (structured counselling programme, information leaflet, follow-up weekly for the first 4 weeks then monthly as needed)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Control group (ad hoc advice from pharmacists)
Number of subjects: 484
Study: 9608351

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 25 mg per day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 50 mg per day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 75 mg per day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 7995316

Group type: EXPERIMENTAL
Intervention: Scopolamine-TTS (1.5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3070050

Group type: EXPERIMENTAL
Intervention: Activity scheduling
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 40
Study: 30014723

Group type: EXPERIMENTAL
Intervention: SSMS (products that appeared as a single serving and contain multiple servings)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SSSS (products that appeared as a single serving and contain a single serving)
Number of subjects: 60

Group type: COMPARATOR
Intervention: MSMS (products that both appear as a multi‐serving and contain multiple servings)
Number of subjects: 60
Study: 28751562

Group type: EXPERIMENTAL
Intervention: ixazomib-lenalidomide-dexamethasone (ixazomib-Rd)
Number of subjects: 722

Group type: COMPARATOR
Intervention: placebo-lenalidomide-dexamethasone (placebo-Rd)
Number of subjects: 722
Study: 26269539

Group type: EXPERIMENTAL
Intervention: IVF-SET
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: IVF-MNC
Number of subjects: 602

Group type: COMPARATOR
Intervention: IUI-COH
Number of subjects: 602

Group type: COMPARATOR
Intervention: IVF-SET vs IUI-COH
Number of subjects: 602

Group type: COMPARATOR
Intervention: IVF-MNC vs IUI-COH
Number of subjects: 602
Study: 24045625

Group type: EXPERIMENTAL
Intervention: Dynamic phase (DP) of lymphoscintigraphy
Number of subjects: 161

Group type: COMPARATOR
Intervention: Early and delayed planar images (EPI and DPI)
Number of subjects: 161
Study: 21113636

Group type: EXPERIMENTAL
Intervention: Caudal epidural injection with 20 ml volume (5 ml contrast, 2 ml Triamcinolone, 13 ml local anaesthetic)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 0° Trendelenburg tilt
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 30° Trendelenburg tilt
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Eradication of lumbar lordosis
Number of subjects: 52
Study: 18290733

Group type: EXPERIMENTAL
Intervention: Ropivacaine (5 injections of 2 mL 0.5% ropivacaine around the ureteral orifice)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (5 injections of 2 mL of 0.9% normal saline)
Number of subjects: 22
Study: 16443721

Group type: EXPERIMENTAL
Intervention: MMPI‐A and MMPI‐2 with 10%, 20%, 30%, 40%, and 50% randomly inserted true or false responses
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison group (normative sample without modifications)
Number of subjects: 100
Study: 12589284

Group type: EXPERIMENTAL
Intervention: Injection molded and microwave polymerized (Microbase)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Injection molded and microwave polymerized (Acron MC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Injection molded and conventionally polymerized (Success)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Compression molded and conventionally polymerized (control group)
Number of subjects: 40
Study: 10831645

Group type: EXPERIMENTAL
Intervention: Calcitriol (2.4+/‐1.0 microg/day, p.o.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9349662

Group type: COMPARATOR
Intervention: MK-677 (25 mg)
Number of subjects: 14
Study: 8449202

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (70 mmol)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: High serum magnesium levels (highest quartile)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Non-AF patients
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: High magnesium levels
Number of subjects: 140
Study: 3534854

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide
Number of subjects: 47
Study: 31344185

Group type: EXPERIMENTAL
Intervention: Low-quality mother-child interaction
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF) <6 months
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Partner does not help with childcare
Number of subjects: 181

Group type: COMPARATOR
Intervention: Postpartum depressive symptoms
Number of subjects: 181
Study: 30194533

Group type: EXPERIMENTAL
Intervention: Multi-component workplace intervention program with environmental changes
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group with feedback and basic occupational health services
Number of subjects: 208
Study: 26650571

Group type: EXPERIMENTAL
Intervention: Medicaid coverage
Number of subjects: 16204

Group type: COMPARATOR
Intervention: Control group (no Medicaid coverage)
Number of subjects: 16204
Study: 24275677

Group type: EXPERIMENTAL
Intervention: Denosumab 60mg every 6 months
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Alendronate 70mg weekly
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 22143734

Group type: EXPERIMENTAL
Intervention: 2% NaF solution
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: GLUMA® (HEMA-G)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: NaF-iontophoresis
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 25
Study: 20643661

Group type: EXPERIMENTAL
Intervention: Screening for congenital heart defects (CHD)
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Overall prevalence of known CHD
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Overall prevalence of CHD in adult Down's syndrome patients
Number of subjects: 1158
Study: 18806016

Group type: EXPERIMENTAL
Intervention: Group 70 (70 bpm)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group 90 (90 bpm)
Number of subjects: 40
Study: 15070605

Group type: EXPERIMENTAL
Intervention: Isosulfan blue dye intradermally at the biopsy site (n=60)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no dye, n=24)
Number of subjects: 84
Study: 11199756

Group type: EXPERIMENTAL
Intervention: Electronic apex locator
Number of subjects: 58

Group type: COMPARATOR
Intervention: Radiographic estimate
Number of subjects: 58
Study: 10170091

Group type: EXPERIMENTAL
Intervention: Permethrin impregnated bednets
Number of subjects: 16800
Study: 7871004

Group type: EXPERIMENTAL
Intervention: ondansetron (4 mg orally)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 3096345

Group type: EXPERIMENTAL
Intervention: Penicillin/Erythromycin prophylaxis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no antibiotic prophylaxis)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no antibiotic prophylaxis) for wounds >1 cm requiring suturing
Number of subjects: 100
Study: 30843703

Group type: EXPERIMENTAL
Intervention: Implementation intention intervention and antismoking messages
Number of subjects: 6155
Study: 29233164

Group type: EXPERIMENTAL
Intervention: Upper thoracic spine mobilization and mobility exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Upper cervical spine mobilization and stabilization exercise
Number of subjects: 32
Study: 24890912

Group type: EXPERIMENTAL
Intervention: Dronabinol therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24162387

Group type: COMPARATOR
Intervention: 5-fluorouracil continuous infusion (5-FUci)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy with new drugs
Number of subjects: 319
Study: 22947287

Group type: EXPERIMENTAL
Intervention: 5.5-mm capsulotomy group (9 eyes)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 6.0-mm capsulotomy group (8 eyes)
Number of subjects: 11
Study: 19409749

Group type: EXPERIMENTAL
Intervention: Didactic learning
Number of subjects: 156

Group type: COMPARATOR
Intervention: Active learning
Number of subjects: 156
Study: 17332131

Group type: COMPARATOR
Intervention: Open reduction and screw fixation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Primary arthrodesis of the medial two or three rays
Number of subjects: 41
Study: 15136776

Group type: EXPERIMENTAL
Intervention: Perceived stress scale
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Depression screener
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Self-efficacy for quitting smoking
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Sense of mastery scale
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Health-related quality of life measures from the Medical Outcomes Study
Number of subjects: 277
Study: 11089516

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 10436948

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil (CAT) 250‐500 mg, twice daily orally for 7‐10 days
Number of subjects: 99

Group type: COMPARATOR
Intervention: Cefixime (CFX) 200 mg, twice daily orally for 7‐10 days
Number of subjects: 99
Study: 8248693

Group type: EXPERIMENTAL
Intervention: Intracervical instillation of prostaglandins E2 (Prepidil)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Intracervical Foley catheter with balloon inflated to 50 cc
Number of subjects: 184

Group type: COMPARATOR
Intervention: Extraamniotic injection of prostaglandins E2 via a Foley catheter with balloon inflated to 50 cc
Number of subjects: 184
Study: 3516907

Group type: EXPERIMENTAL
Intervention: 3% benzydamine cream
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31282567

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg once daily during ICU stay
Number of subjects: 3261

Group type: COMPARATOR
Intervention: Placebo (saline) once daily during ICU stay
Number of subjects: 3261
Study: 28657798

Group type: EXPERIMENTAL
Intervention: Online dating scenario
Number of subjects: 0

Group type: COMPARATOR
Intervention: Offline dating scenario
Number of subjects: 0
Study: 26823213

Group type: EXPERIMENTAL
Intervention: Participatory women's groups facilitated by ASHAs
Number of subjects: 156519

Group type: COMPARATOR
Intervention: Control (no women's groups)
Number of subjects: 156519
Study: 25627344

Group type: EXPERIMENTAL
Intervention: Banking Time intervention
Number of subjects: 59
Study: 23930551

Group type: EXPERIMENTAL
Intervention: GAKIC (10.2 g)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: GAKIC and Placebo
Number of subjects: 7
Study: 20227056

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study: 18823311

Group type: EXPERIMENTAL
Intervention: Triage Risk Stratification Tool (TRST) score of 2 or greater
Number of subjects: 788
Study: 16489434

Group type: EXPERIMENTAL
Intervention: 50 mg baclofen (BAC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 9
Study: 14689713

Group type: EXPERIMENTAL
Intervention: isosorbide dinitrate (ID)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: sustac-forte (SF)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: isosorbide dinitrate retard (IDR)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: trinitrolong (TN)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: ID, SF, IDR
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: TN therapy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: ID, SF
Number of subjects: 109
Study: 10953903

Group type: EXPERIMENTAL
Intervention: Walking intervention for 18 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 97
Study: 8824690

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 46 mg kg-1 infused in 30 min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 46 mg kg-1 infused in 30 min (2 doses)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 11
Study: 1314144

Group type: COMPARATOR
Intervention: ICI 169,369 (30 mg x 2)
Number of subjects: 21

Group type: COMPARATOR
Intervention: ICI 169,369 (80 mg x 2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 21
Study: 30777118

Group type: EXPERIMENTAL
Intervention: 100,000 IU vitamin D3 (two oral doses, once in the fall and once in the winter)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 47